Creatine and Bipolar Risk – The Clinical Trials and Consumer Marketing Gap

Creatine trials recorded manic or hypomanic switching in bipolar patients, while later studies imposed psychiatric exclusions. The retail material investigated carries mood and brain-health claims without reproducing those conditions.

Clinical Evidence of Creatine and Mood Risks

In November 2007, the journal Bipolar Disorders published a preliminary study by Suzana Roitman and colleagues testing creatine monohydrate in patients with treatment-resistant depression. The trial was small. Eight patients with unipolar depression and two with bipolar depression were given 3 to 5 grams of creatine daily for four weeks. Both bipolar patients developed hypomania or mania and were withdrawn from the study.

The authors did not treat this as incidental. They wrote that any use of creatine in patients with a history of bipolar disorder required close psychiatric supervision.

Eleven years later, a larger double-blind placebo-controlled trial produced a similar finding. Ricardo Alexandre Toniolo and colleagues, working at the University of São Paulo, ran a double-blind placebo-controlled study of 35 patients with bipolar depression, giving 6 grams of creatine daily for six weeks. Two of the 17 patients randomly assigned to the active creatine group switched to hypomania or mania early in the trial and dropped out. None of the 18 patients on placebo did.

An earlier precedent exists in a different compound. In 1984, Lipinski and colleagues ran a short open trial of intravenous S-adenosyl-L-methionine, a substance that affects brain energy and methylation. In their eight-patient trial, two patients developed mania or hypomania. That study is not directly reviewed in the current source materials and is drawn from a secondary review paper. It is background only. The compound and route differ from oral creatine, and it is offered here to show that energy-modulating compounds have a longer clinical history of triggering mood switches in susceptible individuals.

Research Community Responses to Creatine Risks

Later psychiatric trial protocols continued to exclude bipolar disorder and other psychiatric conditions.

When In Kyoon Lyoo and colleagues published in the American Journal of Psychiatry in February 2012, they enrolled 52 women with major depressive disorder and gave 5 grams of creatine daily alongside the antidepressant escitalopram. Results were positive: creatine produced faster improvements in depression scores. Bipolar disorder was on the exclusion list. The trial has since been cited in consumer wellness material discussing creatine and depression.

Similar exclusions remained in later protocols. On 4 August 2020, the University of Utah registered trial NCT04504253, testing an aggressive regime of a 20-gram loading dose for one week followed by 5 grams daily as an add-on to electroconvulsive therapy in major depressive disorder. Bipolar I, Bipolar II and personality disorders were explicit exclusions.

A separate bipolar-depression trial was registered but withdrawn before enrolment. Ewha Womans University registered NCT01543139 on 27 February 2012 to test a cytidine- and creatine-containing drug in bipolar depression. The protocol excluded patients on drugs for bipolar depression or any psychotropic medication. Its registry entry now records the trial as withdrawn, with zero actual enrolment. The public record does not state the reason for the withdrawal, and no clinical results exist to compare against Roitman or Toniolo.

Creatine Marketing Claims and Consumer Safety

Retail marketing has carried the positive part of that record without the conditions attached to it.

Thorne’s product pages for ‘Creatine’ and ‘Creatine + Alpha GPC’ claim support for cognitive function and brain function. Their warnings section covers hypersensitivity, pregnancy and the New York restriction on sales to under-18s. Bipolar disorder is not mentioned. Manic switching is not mentioned. The requirement for psychiatric supervision set out in Roitman 2007 is not mentioned.

Mindbodygreen markets ‘creatine brain+’ as a mental clarity and mood product, adopting a clinical-efficacy framing without listing psychiatric exclusions.

The Wellness London goes further in its retail copy, describing the underlying evidence as ‘genuinely settled’ and promoting daily use for ‘memory, mood and mental energy’. No psychiatric contraindications are given.

Doses named in these product pages sit inside the same 3 to 6 gram daily range as the trials that recorded manic switching. A shopper with bipolar depression buying 5 grams a day from Thorne or The Wellness London is consuming the same daily amount that Roitman’s authors said required close psychiatric supervision.

The clinician-adjacent platform Ubie carries a note flagging bipolar caution, describing the risk of a manic switch and advising against self-prescribing. That warning does not appear in the retail material examined.

Biological Mechanisms of Creatine and Brain Energy

Marketing and the psychiatric literature reach for the same biological argument. They do not draw the same conclusion from it.

Retail copy is straightforward. The brain uses roughly 20 per cent of the body’s energy. Creatine acts as an energy buffer, converting to phosphocreatine and helping the cell keep its main fuel supply topped up. This energy-supporting function is presented as a general benefit for brain function.

Psychiatric literature discusses the same energy-buffering mechanism in a different context. Bipolar disorder is understood in this literature as a condition of abnormal brain energy handling. Manic states are associated with elevated energy activity, and depressed states with reduced activity. Adding a strong energy buffer for a patient prone to switching is proposed as a plausible explanation for the manic episodes recorded during the trials.

The link remains a working explanation rather than a settled single-cause pathway.

Clinical Trial Exclusions and Consumer Labelling

The clinical trials and consumer material examined here do not carry the same information.

The creatine trials in this record declared psychiatric exclusion criteria in advance, including bipolar disorder or wider psychiatric conditions. The retail material examined here carries cognitive or mood claims without reproducing those participant exclusions.

Nothing in the available record establishes that the omission was deliberate.

Broader Context of Creatine Supplement Safety

Two further bodies of evidence sit next to this question, and both are limited in what they can show.

Published case reports have linked heavy energy drink consumption to psychosis and mania. Those drinks combine caffeine, taurine and creatine, so the case series cannot isolate creatine as the causal variable.

Unredacted FDA MedWatch or MHRA Yellow Card data directly linking retail creatine to hospitalisations for acute mania is not present in the public record supplied for this investigation. Its absence from this record does not establish that no such reports exist.

Consumer-use survey material indicates that the retail user base extends beyond the athletic population creatine was originally marketed to, into what industry reporting describes as healthy ageing and women’s health.

Source Box

Sources include: Suzana Roitman and colleagues’ 2007 ‘Creatine monohydrate in resistant depression: A preliminary study’; Ricardo Alexandre Toniolo and colleagues’ 2018 ‘A randomized, double-blind, placebo-controlled, proof-of-concept trial of creatine monohydrate as adjunctive treatment for bipolar depression’; In Kyoon Lyoo and colleagues’ 2012 ‘A Randomized, Double-Blind Placebo-Controlled Trial of Oral Creatine Monohydrate Augmentation for Enhanced Response to a Selective Serotonin Reuptake Inhibitor in Women With Major Depressive Disorder’; ClinicalTrials.gov records NCT04504253 and NCT01543139; Thorne’s ‘Creatine’ product material, The Wellness London’s ‘Creatine’ retail page and Ubie’s ‘Safety Alert: Why People with Bipolar Disorder Should Use Caution’.